Lack of pharmacokinetic interaction between oxcarbazepine and lamotrigine.

about

Rationalization and prediction of in vivo metabolite exposures: the role of metabolite kinetics, clearance predictions and in vitro parameters.Pharmacokinetics, toxicology and safety of lamotrigine in epilepsy.The effect of age and comedication on lamotrigine clearance, tolerability, and efficacy.

P2860

Q34071827-3282EA2D-99CE-473B-AB72-A4FCDE23BDF4 Q36662898-B071ABC4-C80E-472F-9B0D-355B22D9D63B Q48288617-CA20C005-FE5E-454A-95CE-86309FBF150E

P2860

Lack of pharmacokinetic interaction between oxcarbazepine and lamotrigine.

Item

http://www.wikidata.org/entity/Q46624949

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh-hant

name

Lack of pharmacokinetic interaction between oxcarbazepine and lamotrigine.

@en

Lack of pharmacokinetic interaction between oxcarbazepine and lamotrigine.

@nl

type

Item

label

Lack of pharmacokinetic interaction between oxcarbazepine and lamotrigine.

@en

Lack of pharmacokinetic interaction between oxcarbazepine and lamotrigine.

@nl

prefLabel

Lack of pharmacokinetic interaction between oxcarbazepine and lamotrigine.

@en

Lack of pharmacokinetic interaction between oxcarbazepine and lamotrigine.

@nl

P1476

Lack of pharmacokinetic interaction between oxcarbazepine and lamotrigine.

@en

P2093

Jagdev Sidhu

http://www.w3.org/2001/XMLSchema#string

Joanne Palmer

http://www.w3.org/2001/XMLSchema#string

Jochen G W Theis

http://www.w3.org/2001/XMLSchema#string

John Ascher

http://www.w3.org/2001/XMLSchema#string

Jonathan Bullman

http://www.w3.org/2001/XMLSchema#string

Sarah Job

http://www.w3.org/2001/XMLSchema#string

P2860

Time course of recovery of cytochrome p450 3A function after single doses of grapefruit juice

Oxcarbazepine.

Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans.

Lamotrigine. A review of its pharmacological properties and clinical efficacy in epilepsy.

Oxcarbazepine in the treatment of epilepsy.

Place of polytherapy in the early treatment of epilepsy.

Clinical pharmacokinetics of oxcarbazepine.

Clinical implications of enzyme induction and enzyme inhibition.

Clinical pharmacology and pharmacokinetics of oxcarbazepine.

Time course of lamotrigine de-induction: impact of step-wise withdrawal of carbamazepine or phenytoin.

P2888

sj.npp.1300831

P304

2269-2274

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.NPP.1300831

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2005-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7694035

http://www.w3.org/2001/XMLSchema#string

P698

16052246

http://www.w3.org/2001/XMLSchema#string

Lack of pharmacokinetic interaction between oxcarbazepine and lamotrigine.

about

P2860

P2860

Lack of pharmacokinetic interaction between oxcarbazepine and lamotrigine.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P577

P5875

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P577

P5875

P698